Peroxisome Proliferator-Activated Receptor-Gamma Agonist 4-O-Methylhonokiol Induces Apoptosis by Triggering the Intrinsic Apoptosis Pathway and Inhibiting the PI3K/Akt Survival Pathway in SiHa Human Cervical Cancer Cells

被引:18
作者
Hyun, Seungyeon [1 ]
Kim, Man Sub [1 ]
Song, Yong Seok [1 ]
Bak, Yesol [1 ]
Ham, Sun Young [1 ]
Lee, Dong Hun [1 ]
Hong, Jintae [2 ,3 ]
Yoon, Do Young [1 ]
机构
[1] Konkuk Univ, Biomol Informat Ctr, Dept Biosci & Biotechnol, Seoul 143701, South Korea
[2] Chungbuk Natl Univ, Coll Pharm, Cheongju 361463, South Korea
[3] Chungbuk Natl Univ, Med Res Ctr, Cheongju 361463, South Korea
关键词
4-O-Methylhonokiol; cervical cancer; PPAR gamma agonist; apoptosis; PPAR-GAMMA; P21-MEDIATED SUPPRESSION; TUMOR-GROWTH; HONOKIOL; GENE; PAPILLOMAVIRUS; AMPLIFICATION; INVOLVEMENT; DOWNSTREAM; EXPRESSION;
D O I
10.4014/jmb.1411.11073
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
4-O-Methylhonokiol (MH), a bioactive compound derived from Magnolia officinalis, is known to exhibit antitumor effects in various cancer cells. However, the precise mechanism of its anticancer activity in cervical cancer cells has not yet been studied. In this study, we demonstrated that MH induces apoptosis in SiHa cervical cancer cells by enhancing peroxisome proliferator-activated receptor-gamma (PPAR gamma) activation, followed by inhibition of the PI3K/Akt pathway and intrinsic pathway induction. MH upregulated PPAR gamma and PTEN expression levels while it decreased p-Akt in the MH-induced apoptotic process, thereby supporting the fact that MH is a PPAR gamma activator. Additionally, MH decreased the expression of Bcl-2 and Bcl-XL, inducing the intrinsic pathway in MH-treated SiHa cells. Furthermore, MH treatment led to the activation of caspase-3/caspase-9 and proteolytic cleavage of polyADP ribose polymerase. The expression levels of Fas (CD95) and E6/E7 oncogenes were not altered by MH treatment. Taken together, MH activates PPAR gamma/PTEN expression and induces apoptosis via suppression of the PI3K/Akt pathway and mitochondria-dependent pathways in SiHa cells. These findings suggest that MH has potential for development as a therapeutic agent for human cervical cancer.
引用
收藏
页码:334 / 342
页数:9
相关论文
共 39 条
  • [1] Facile purification of honokiol and its antiviral and cytotoxic properties
    Amblard, Franck
    Delinsky, David
    Arbiser, Jack L.
    Schinazi, Raymond F.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (11) : 3426 - 3427
  • [2] Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy
    Arora, S.
    Singh, S.
    Piazza, G. A.
    Contreras, C. M.
    Panyam, J.
    Singh, A. P.
    [J]. CURRENT MOLECULAR MEDICINE, 2012, 12 (10) : 1244 - 1252
  • [3] The causal relation between human papillomavirus and cervical cancer
    Bosch, FX
    Lorincz, A
    Muñoz, N
    Meijer, CJLM
    Shah, KV
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (04) : 244 - 265
  • [4] The phosphoinositide 3-kinase pathway
    Cantley, LC
    [J]. SCIENCE, 2002, 296 (5573) : 1655 - 1657
  • [5] Chen LM, 2005, INT J MOL MED, V15, P617
  • [6] How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?
    Chipuk, Jerry E.
    Green, Douglas R.
    [J]. TRENDS IN CELL BIOLOGY, 2008, 18 (04) : 157 - 164
  • [7] Cellular survival: a play in three Akts
    Datta, SR
    Brunet, A
    Greenberg, ME
    [J]. GENES & DEVELOPMENT, 1999, 13 (22) : 2905 - 2927
  • [8] Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
    Datta, SR
    Dudek, H
    Tao, X
    Masters, S
    Fu, HA
    Gotoh, Y
    Greenberg, ME
    [J]. CELL, 1997, 91 (02) : 231 - 241
  • [9] Downstream signalling events regulated by phosphatidylinositol 3-kinase activity
    Duronio, V
    Scheid, MP
    Ettinger, S
    [J]. CELLULAR SIGNALLING, 1998, 10 (04) : 233 - 239
  • [10] Peroxisome proliferator-activated receptor γ induces pancreatic cancer cell apoptosis
    Eibl, G
    Wente, MN
    Reber, HA
    Hines, OJ
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 287 (02) : 522 - 529